CGTs For HIV Suppression With Addimmune's Dr. Marcus Conant
Source: Cell & Gene
![23_12_CGPodcast_1280x720_Ep75 23_12_CGPodcast_1280x720_Ep75](https://vertassets.blob.core.windows.net/image/7eb9cffd/7eb9cffd-9b3b-47ce-8653-975b72bfce42/375_250-23_12_cgpodcast_1280x720_ep75.jpg)
On this episode of Cell & Gene: The Podcast, Addimmune CMO, Dr. Marcus Conant, shares the why behind cell and gene therapy to treat HIV, and explains the company's lead asset, AGT103-T, which is designed to provide broad protection using silencing RNA to inhibit binding/entry of the virus, halt replication, and prevent escape.
access the Podcast!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
This website uses cookies to ensure you get the best experience on our website. Learn more